CAPLIN POINT, a company involved in the laboratory business, has released the results of the second quarter of the current financial year. The company has informed in the exchange filing that its profits and earnings have increased. The consolidated profit of the company has increased from Rs 115 crore to Rs 131 crore on an annual basis. The consolidated earnings of the company have increased from Rs 410 crore to Rs 483 crore. Talking about the EBITDA of the company, it has increased from Rs 137 crore to Rs 165 crore. EBITDA margin has increased from 33.4% to 34.2%.


CAPLIN POINT LABORATORIES, a midcap pharmaceutical company, has hit an all-time high in its stock price on November 7, 2024. The stock has performed well, with its current price of Rs 2158.2 only 2.84% away from its 52-week high.

It has outperformed the sector by 1.85% and has been in profit for the last 3 days in a row, adding 7.07% to the returns. The stock is trading above its moving average, which indicates a positive trend. In the last one year, it has shown a spectacular growth of 97.88%, which reflects its strong performance in the pharmaceutical industry.
 

If we look at the
stock performance of the company, it has given a return of 5.43 percent in 1 week, 11.31 percent in 1 month and 36 percent in 3 months. Investors have earned a return of 99.08 percent in 1 year and 155 percent in 3 years from the company.

Talking about the company's stake, promoters have 70.56 percent, retail 23.92 percent, foreign institutional investment 3.71 percent and domestic institutional investors have 1.84 percent stake.